Trial
NCT03515707
Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Fred Hutchinson Cancer Center
Collaborators
National Cancer Institute (NCI)
Condition
Acute Myeloid Leukemia
Intervention
Autologous Hematopoietic Stem Cell Transplantation
Why stopped
PI recommended closure
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-02-01